Mulpleo▼ (lusutrombopag) Prescribing Information

Mulpleo (lusutrombopag) has been granted a marketing authorisation in the European Union and the UK for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures.

Lusutrombopag has not been granted a marketing authorisation in Switzerland and is therefore not authorised for use in Switzerland.

Further, lusutrombopag has been approved in Japan for the improvement of thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures, and in the USA for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Prescribing information (PI) may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SmPC).

For the SmPC in English, visit here.

For the SmPC in other languages, visit here.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported via the national reporting systems accessible here.

Adverse events should also be reported to Shionogi on
Tel: +44 (0)203 053 4190 or via contact@shionogi.eu.

NP-EU-LUS-0093
Prepared July 2021